Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to enhance its market reach and sales [2]. Group 2: Financial Reporting Issues - Simulations Plus claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears the integration was unsuccessful and internal controls were ineffective [3]. - On April 15, 2025, the company appointed Grant Thornton LLP as its new auditor, which later raised concerns about the company's financial reporting [4][5]. Group 3: Stock Performance and Market Reaction - Following the announcement of disappointing preliminary financial results for Q3 2025 on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and acknowledged ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Group 3: Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Simulations Plus, Inc. for potential violations of securities laws [1] - The investigation centers on whether Simulations Plus issued false or misleading statements and failed to disclose relevant information to investors [2] - Following the Q3 2025 earnings report, Simulations Plus reported sales of $20.4 million, which was below the consensus estimate of $20.9 million, leading to a decline in the company's shares [2] Group 2 - The preliminary third-quarter sales figures released in June indicated lower expectations at $19 million to $20 million, compared to a consensus of $22.78 million [2]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following issues related to its acquisition of Pro-ficiency Holdings, Inc. and subsequent financial reporting problems [1][2][3]. Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to enhance its market reach and sales [2][3]. Group 2: Financial Reporting Issues - The company claimed that the integration of Pro-ficiency would double its total addressable market and significantly contribute to sales, but it appears that the integration was not successful and internal controls were ineffective [3]. - On April 15, 2025, Simulations Plus appointed Grant Thornton LLP as its new auditor, but shortly after, it reported disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties [4]. Group 3: Stock Performance - Following the announcement of disappointing financial results on June 11, 2025, Simulations Plus's stock price dropped by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - On July 14, 2025, the company reported a $77.2 million charge related to prior acquisitions and dismissed Grant Thornton, which raised concerns about its internal controls and financial reporting [5]. - The stock price fell again by $4.50, nearly 26%, from $17.47 to $12.97 per share after the news of the impairment charge and auditor dismissal [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported disappointing preliminary financial results for Q3 2025, citing market uncertainties as significant headwinds, leading to a stock price drop of over 24% [4] - The company announced a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results, which contributed to a further decline in stock price of nearly 26% [5] - The dismissal of Grant Thornton LLP as the company's auditor raised concerns about internal controls and segment reporting, with the auditor identifying unresolved issues [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls, but evidence suggests struggles with integration and control effectiveness [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. experienced a significant decline in share price, approximately 25%, following the announcement of a $67.3 million net loss for Q3 2025, which included a $77.2 million impairment charge and the dismissal of its independent auditor, Grant Thornton [1]. Financial Performance - The company reported a net loss of $67.3 million for Q3 2025, which was attributed to a $77.2 million impairment charge [1]. - The impairment charge involved adjusting the book value of its assets to align with current market values [4]. Auditor Dismissal - Simulations Plus terminated its engagement with Grant Thornton on July 9, 2025, after hiring the firm on April 15, 2025 [1][4]. - The company cited issues related to segment reporting and internal controls over financial reporting as reasons for the auditor change, stating that these matters could not be finalized for its May 31, 2025, quarterly report [5]. Investigation - Hagens Berman, a national shareholders rights firm, has initiated an investigation into whether Simulations Plus misled investors regarding its asset valuations and the reasons for dismissing Grant Thornton [2][3]. - Grant Thornton disputed Simulations Plus's account of the dismissal, indicating that it had raised specific concerns about the company's financial statements during its review [6]. Shareholder Actions - Shareholders who suffered substantial losses are encouraged to submit their losses to assist in the investigation [2][7].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3]. Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls over financial reporting, which appears to be misleading as the company struggled with integration and lacked effective controls [3]. - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4]. - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5]. Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5].